{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-026089","form_type":"8-K","ticker":"RANI","cik":"0001856725","company_name":"Rani Therapeutics Holdings, Inc.","filed_at":"2022-12-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:52.795268+00:00","generated_at":"2026-06-21T09:10:56.088751+00:00","sec_items":["7.01","9.01","8.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"RT-102 repeat-dose Phase 1 meets endpoints; 91% delivery success, high bioavailability, supports Phase 2","bullets":["No serious adverse events; all 10 participants completed 7-day daily dosing.","RaniPill GO delivered PTH with 91% overall success; Day 7 success rate 100%.","RT-102 showed high PTH bioavailability vs subcutaneous injection in Part 1.","Company expects to initiate Phase 2 trial of RT-102 in osteoporosis in H2 2023.","Over 185 RaniPill capsules administered in clinical studies; platform advancing for multiple programs."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-026089","json":"https://secwatch.observer/filing/0000950170-22-026089.json","markdown":"https://secwatch.observer/filing/0000950170-22-026089.md","text":"https://secwatch.observer/filing/0000950170-22-026089.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1856725/000095017022026089/0000950170-22-026089-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1856725/000095017022026089/rani-20221206.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T09:10:56.088751+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}